29 August 2022

Selected Scientific Publications based on our PQR309 compound

Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib(PQR309) in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
Faye M Johnson, Filip Janku, et al. The Oncologist 2023

Topical Bimiralisib Shows Meaningful Cutaneous Drug Levels in Healthy Volunteers and Mycosis Fungoides Patients but No Clinical Activity in a First-in-Human, Randomized Controlled Trial
Wind SS, et al.  Cancers (Basel) 2022

Novel patient-derived xenograft and cell line models for therapeutic screening in NF2-associated schwannoma
Zhao F, et al.  J Pathol. 2021

Exon–Intron Differential Analysis Reveals the Role of Competing Endogenous RNAs in Post-Transcriptional Regulation of Translation
Munz N, et al.  Noncoding RNA 2021

Suppression of PI3K/Akt/mTOR/c-Myc/mtp53 Positive Feedback Loop Induces Cell Cycle Arrest by Dual PI3K/mTOR Inhibitor PQR309 in Endometrial Cancer Cell Lines
Hsin IL, et al.  Cells 2021

A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma
Collins GP, et al.  Hemasphere 2021

PI3K/mTORC1/2 inhibitor PQR309 inhibits proliferation and induces apoptosis in human glioblastoma cells
Yang K, et al.  Oncol Rep 2020

Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models
Von Achenbach C, et al.  J Neurochem 2020

PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy
Tarantelli C, et al.  Clin Cancer Res 2018

First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
Wicki A, et al.  Eur J Cancer 2018

5-(4,6-Dimorpholino-1,3,5-triazin-2-yl) -4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology
Beaufils F, et al.  J Med Chem 2017